Results 201 to 210 of about 15,263 (254)

Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study

The Laryngoscope, Volume 136, Issue 9, Page 3744-3751, September 2026.
The impact of dupilumab on nasal airway patency and airflow is not uniform. It is more pronounced in the middle and superior, but not inferior meatus. These unique regional changes significantly correlate with and potentially drive the improvement in patient symptoms.
Ahmad Odeh, Zhenxing Wu, Nidhi Jha, Aspen R. Schneller, James Mihalich, Zachary T. Root, Christopher Brooks, Casey Curtis, Monica Kraft, Kara Wada, Bradley A. Otto, Kathleen M. Kelly, Kai Zhao   +12 more
wiley   +1 more source

Dupilumab in Severe Atopic Dermatitis With Phosphoglucomutase 3 Deficiency. [PDF]

Scand J Immunol
Aydin M, Meric Z, Gumus DD, Tufan A, Demir Y, Zubarioglu T, Kiykim E, Aktuglu-Zeybek C, Oba MÇ, Yucel E, Kiykim A.   +10 more
europepmc   +1 more source

Demodex Infestation in Patients With Atopic Dermatitis Treated With Dupilumab: A Case–Control Study

The Journal of Dermatology, Volume 53, Issue 9, Page 1261-1266, September 2026.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease in which dupilumab, an interleukin‐4 receptor alpha antagonist, has become a cornerstone therapy for moderate‐to‐severe disease. However, persistent facial and neck erythema and related symptoms have been increasingly reported during dupilumab treatment, and the underlying ...
Pinar Dursun, Ayse Nur Saribas Yildirim, Ayca Yazici   +2 more
wiley   +1 more source

Monoclonal antibody therapy in patients with severe asthma and COPD: rethinking treatment pathways and success. [PDF]

BMJ Open Respir Res
Burton R, Puthoor M, Fyles F, Lewis L, Joplin H, Burhan H.   +5 more
europepmc   +1 more source

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual‐Center Study

The Journal of Dermatology, Volume 53, Issue 9, Page 1353-1357, September 2026.
ABSTRACT Biologic therapies targeting Type 2 inflammation are increasingly used in bullous pemphigoid, yet the relationship between pruritus and distinct disease domains remains incompletely defined. We conducted a retrospective international dual‐center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab ...
Ruggero Cascio Ingurgio, Angela Alfano, Aalia Syed, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Dedee F. Murrell   +6 more
wiley   +1 more source

The evaluation of cytokine profiles in atopic dermatitis patients treated with dupilumab: association with ocular complications. [PDF]

Front Immunol
Čelakovská J, Čermáková E, Boudkova P, Andrýs C.   +3 more
europepmc   +1 more source

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing—Recommendations on Best Practice (Update 2026)

Contact Dermatitis, Volume 95, Issue 3, Page 237-275, September 2026.
ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter, Olivier Aerts, Tove Agner, Richard Brans, Magnus Bruze, Alicia Cannavó, Marie‐Noёlle Crépy, Ana M. Giménez‐Arnau, Margarida Gonçalo, An Goossens, Swen M. John, Carola Lidén, Suzana Ljubojević Hadžavdić, Vera Mahler, Mihaly Matura, Esen Özkaya, Maria Pesonen, Nadia Raison‐Peyron, Thomas Rustemeyer, Radoslaw Spiewak, Luca Stingeni, Ian R. White, S. Mark Wilkinson, Jeanne Duus Johansen   +23 more
wiley   +1 more source

Emerging role of Dupilumab for COPD with type 2 inflammation. [PDF]

Afr J Thorac Crit Care Med
Manga J.
europepmc   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, Volume 65, Issue 9, Page 1846-1855, September 2026.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source